QIAGEN N.V. (QGEN)
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.
Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Understanding Qiagen (QGEN) Reliance on International Revenue
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Qiagen Q2 Earnings Call Highlights
Qiagen NYSE: QGEN reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates.
Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript
Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
Qiagen (QGEN) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.63 per share a year ago.
Qiagen (QGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Qiagen: New Launches Signal A Turnaround
Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation.
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use
QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.
